An FTO analysis identifies in-force third-party patent claims that could be infringed by a planned product, and assesses design-around or licensing options. Distinct from patentability - a company can have its own patent and still infringe another. The analysis is usually done by patent counsel for each target market. Investors and acquirers often ask for FTO opinions during diligence.

Why it matters

Investor and acquirer DD requires clean FTO opinions. Late-stage FTO surprises can derail financings and M&A.

Common pitfalls

•Failing to conduct FTO analysis early in the product development lifecycle can lead to significant redesigns, delays, or even project cancellation.
•Assuming that obtaining your own patent guarantees freedom to operate is a common and dangerous misconception, as separate patents may exist that cover aspects of your device.
•Neglecting to update FTO analyses throughout the product lifecycle as new patents are granted or product designs evolve can expose a company to infringement risks.
•Relying solely on in-house legal opinions without seeking external expert review for complex FTO assessments can lead to overlooked risks.
•Ignoring FTO for software components or ancillary devices that integrate with the main MedTech product can create unexpected legal vulnerabilities.

Sources

Open full page

Select term B to compare.

Why compare MedTech terms side by side?

MedTech terminology is full of pairs that look interchangeable but carry very different regulatory, clinical, and commercial consequences. Picking the wrong framework, pathway, or standard early in a project can add months to a submission, invalidate clinical evidence, or trigger an audit finding. Side-by-side comparison is the fastest way to surface those differences before they become costly mistakes.

Each comparison on this page pulls from the same vendor-neutral, sourced definitions used throughout the MedTech Terms glossary. You see the one-line summary, the formal definition, why it matters in practice, common pitfalls, and the primary sources (FDA guidance, EU MDR/IVDR articles, ISO/IEC standards, MDCG documents, IMDRF principles) that back each entry. That makes the comparison defensible in regulatory strategy memos, design reviews, and submission narratives.

Common comparison patterns

Regulatory pathway choice - 510(k) vs PMA, 510(k) vs De Novo, Abbreviated vs Special 510(k).
Quality systems - QSR vs ISO 13485, QMSR vs QSR.
Software classification - SaMD vs SiMD, Locked vs adaptive AI.
EU frameworks - MDR vs IVDR, CE Mark vs UKCA.
Cybersecurity artifacts - SPDX vs CycloneDX SBOM, CVE vs CVSS.
Post-market actions - Recall vs field action, Removal vs correction.

How to use this tool

Pick term A and term B from the dropdowns, or click a preset above. The URL updates with both slugs so you can bookmark or share the exact comparison with a colleague, a notified body reviewer, or your regulatory consultant. Click Open full page on either side for the complete entry, including FAQs, related terms, and the full citation list. If you are not sure which term to start with, browse the Categories view or the A-Z index.

MedTech Terms is a vendor-neutral community resource sponsored by Blue Goat Cyber. Definitions are written for educational use and are not legal or regulatory advice.